AcelRx Pharmaceuticals Draws Warning Letter for Misleading Claims

By Sam | March 1, 2021

The FDA’s Office of Prescription Drug Promotion (OPDP) issued a warning letter to AcelRx Pharmaceuticals over false and misleading claims it made for its oral opioid Dsuvia (sufentanil).
Source: Drug GMP Report

Posted in Drug GMP Report